% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kilimann:139622,
      author       = {Kilimann, Ingo and Thyrian, Jochen René and Hoffmann,
                      Wolfgang and Teipel, Stefan J},
      title        = {{T}ranslation of imaging biomarkers from clinical research
                      to healthcare.},
      journal      = {Zeitschrift für Gerontologie und Geriatrie},
      volume       = {50},
      number       = {S2},
      issn         = {0948-6704},
      address      = {Heidelberg},
      publisher    = {Springer Medizin},
      reportid     = {DZNE-2020-05944},
      pages        = {84-88},
      year         = {2017},
      abstract     = {The use of biomarkers for diagnostics of Alzheimer's
                      disease (AD) has increased over the last years in
                      specialized care and experimental settings. With the
                      possibly upcoming availability of disease-modifying
                      therapeutic agents, the diagnostics and treatment of
                      patients with cognitive impairment will change. Biomarkers
                      will be used as theranostic markers for case finding. The
                      development and evaluation of biomarkers can be framed in
                      a phase model from preclinical studies through trials in
                      expert center settings to the evaluation of biomarkers in
                      primary care, up to testing the efficacy and the impact of
                      biomarkers on the healthcare system. Hippocampal volumetry
                      is the most accepted and in-depth tested biomarker for AD
                      diagnostics and prediction of the course. Therefore,
                      hippocampus volumetry is used to illustrate the phase model
                      of biomarker development and present the milestones already
                      achieved and questions still to be resolved.},
      keywords     = {Alzheimer Disease: diagnostic imaging / Alzheimer Disease:
                      metabolism / Alzheimer Disease: pathology / Biomarkers:
                      cerebrospinal fluid / Brain: diagnostic imaging / Brain:
                      metabolism / Brain: pathology / Health Services Research:
                      organization $\&$ administration / Humans / Molecular
                      Imaging: methods / Positron-Emission Tomography: methods /
                      Reproducibility of Results / Sensitivity and Specificity /
                      Translational Medical Research: organization $\&$
                      administration / Biomarkers (NLM Chemicals)},
      cin          = {AG Teipel / AG Thyrian / AG Hoffmann},
      ddc          = {150},
      cid          = {I:(DE-2719)1510100 / I:(DE-2719)1510800 /
                      I:(DE-2719)1510600},
      pnm          = {344 - Clinical and Health Care Research (POF3-344)},
      pid          = {G:(DE-HGF)POF3-344},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:28405748},
      doi          = {10.1007/s00391-017-1225-3},
      url          = {https://pub.dzne.de/record/139622},
}